OncoMatch

OncoMatch/Clinical Trials/NCT06925724

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Is NCT06925724 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Ivonescimab for endometrial cancer.

Phase 2RecruitingMemorial Sloan Kettering Cancer CenterNCT06925724Data as of Sep 2026

Treatment: IvonescimabThe researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Ivonescimab

Cancer type

Endometrial Cancer

Cervical Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Female only

Prior therapy

Min 1 prior line

Must have received: platinum-based chemotherapy

has progressed after treatment with at least one platinum-based regimen

Lab requirements

Blood counts

Absolute neutrophil count (ANC) ≥1500/mm3 (≥1.5 × 10^3/µL); Platelets ≥100,000/µL; Hemoglobin ≥9.0 g/dL; International Normalized Ratio (INR) ≤1.5

Kidney function

Creatinine clearance (CrCl) ≥ 30 mL/min using the Cockcroft-Gault formula; Urine protein < 2+ (or 24 hour urine protein quantification < 1.0 g)

Liver function

Total bilirubin ≤1.5 ×ULN (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled); AST and ALT ≤2.5 × ULN (≤5 × ULN for participants with liver metastases); TSH within normal limits. If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal free T4 level is required.

Have adequate laboratory values as defined in the following table: Hematologic, Renal, Hepatic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
  • Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities) · Commack, New York
  • Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06925724 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received platinum-based chemotherapy.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify